Jiangsu Sinopep-Allsino Biopharmaceutical Balance Sheet Health
Financial Health criteria checks 5/6
Jiangsu Sinopep-Allsino Biopharmaceutical has a total shareholder equity of CN¥2.6B and total debt of CN¥1.3B, which brings its debt-to-equity ratio to 49.4%. Its total assets and total liabilities are CN¥4.4B and CN¥1.8B respectively. Jiangsu Sinopep-Allsino Biopharmaceutical's EBIT is CN¥471.2M making its interest coverage ratio 22.8. It has cash and short-term investments of CN¥661.5M.
Key information
49.4%
Debt to equity ratio
CN¥1.30b
Debt
| Interest coverage ratio | 22.8x |
| Cash | CN¥661.51m |
| Equity | CN¥2.64b |
| Total liabilities | CN¥1.80b |
| Total assets | CN¥4.44b |
Recent financial health updates
No updates
Recent updates
Should You Be Adding Jiangsu Sinopep-Allsino Biopharmaceutical (SHSE:688076) To Your Watchlist Today?
Sep 26
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHSE:688076) Stocks Shoot Up 32% But Its P/E Still Looks Reasonable
Jun 23Jiangsu Sinopep-Allsino Biopharmaceutical's (SHSE:688076) Shareholders May Want To Dig Deeper Than Statutory Profit
Apr 04There's Reason For Concern Over Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s (SHSE:688076) Massive 27% Price Jump
Mar 04Financial Position Analysis
Short Term Liabilities: 688076's short term assets (CN¥1.8B) exceed its short term liabilities (CN¥1.4B).
Long Term Liabilities: 688076's short term assets (CN¥1.8B) exceed its long term liabilities (CN¥366.9M).
Debt to Equity History and Analysis
Debt Level: 688076's net debt to equity ratio (24.3%) is considered satisfactory.
Reducing Debt: 688076's debt to equity ratio has increased from 16.8% to 49.4% over the past 5 years.
Debt Coverage: 688076's debt is well covered by operating cash flow (29.3%).
Interest Coverage: 688076's interest payments on its debt are well covered by EBIT (22.8x coverage).